The Top Five Pharma Stories Of 2023

11 Jan 2024

The biopharma new year begins as the J.P. Morgan Healthcare Conference ends so here in no particular order, Scrip takes a look at five of the biggest stories of 2023, once again a year of highs and lows for the industry.

Light Bulbs Stars — • Source: Shutterstock

Breakthrough treatments are fortunately quite frequent but in 2023, the most excitement for an innovative product was reserved for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG's Casgevy (exagamglogene autotemcel), the first-ever CRISPR gene-edited medicine to get approval, firstly in the UK and then in the US, for sickle cell disease and transfusion-dependent beta thalassemia. (Also see "Vertex Achieves Gene-Editing Milestone With First Ever CRISPR Therapy Approval" - Scrip, 16 November, 2023.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

14 Mar 2025

• By Eleanor Malone

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

21 Feb 2025

• By Eleanor Malone

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

M&A Takeoff May Be Delayed, Experts Predict

12 Feb 2025

• By Jessica Merrill

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.

10 Clinical Trials To Look Out For In 2025

07 Feb 2025

• By Alexandra Shimmings

Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.

Can European Biotech Survive And Thrive In Era Of Instability?

30 Apr 2025

• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.